RxDoctor Payments Data

Angela McCool-Pearson

Obstetrics & Gynecology · Fairhope, ALNPI 1154445724

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $45,450 of the $57,136 with a category attached, or 79.5%. AbbVie accounts for 92.9% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $28,861 and has fallen 99.9% since, to $38 in 2025. Among obstetrics & gynecology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$57,136in general payments, 2019–2025

Across 184 payments — averaging $310.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$53K
  • Therapeuticsmd, Inc.$1K
  • Applied Medical Resources Corporation$1K
  • Coloplast$436
  • Intuitive Surgical$277
  • Galderma Laboratories, L.p.$201
  • plus $532 from 19 others
$225,130in research payments, 2019–2025

Across 124 payments — averaging $1815.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$225K

What the payments were for

  • Consulting fees$1,2002%
  • Speaking & faculty fees$45,45080%
  • Travel & lodging$6,96112%
  • Food & beverage$3,4016%
  • Education$1240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$57,136 in reported general payments places this provider in the 95th percentile of 537 obstetrics & gynecology providers in Alabama.

See all obstetrics & gynecology providers in Alabama

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron11$14,433
PremarinEstrogens, Conjugated26$8,491
Estradiol124$8,102
ProgesteroneProgesterone, Micronized49$3,679
Estradiol (Twice Weekly)Estradiol21$3,165
ValacyclovirValacyclovir Hcl17$623
Clobetasol Propionate12$340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$59$14,43311 claims
PfizerPremarin$98$8,49126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 537 obstetrics & gynecology providers in Alabama.

Other obstetrics & gynecology in Fairhope

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →